



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230MH1990PLC058071

(Rs. In Lakhs)						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.03.2016						
Sr. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
		Audited	Unaudited	Audited	Audited	Audited
1	(a) Net Sales/Income from Operations	515.73	447.86	447.46	1885.63	1867.79
	(b) Other Operating Income	0.00	0.00	0.00	29.68	12.88
	Total Income From Operations (Net)	515.73	447.86	447.46	1915.31	1880.67
2	Expenses					
	a. Cost of Materials Consumed	- 234.11	249.92	185.92	959.36	913.34
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-29.39	-57.89	-2.69	-29.39	-1.33
	d. Employee Benfit Expenses	123.63	132.24	121.00	483.53	408.36
	e. Depreciation and Amortisation Expense	-34.59	31.47	31.01	59.81	131.23
	f.Loss/Gain on Foreign Exchange Transactions	0.00	0.00	0.00	0.00	-0.34
	g. Other expenditure	114.13	93.80	78.63	388.69	376.94
	Total Expenses	407.89	449.54	413.87	1862.00	1828.20
3	Profit from operations before Other Income and Finance Cost (1-2)	107.84	-1.68	33.59	53.31	52.47
4	Other Income	-9.28	2.73	0.06	0.00	2.03
5	Profit before Fiinance Costs (3+4)	98.56	1.05	33.65	53.31	54.50
6	Finance Costs	10.63	27.42	13.69	67.03	53.81
7	Profit/ Loss before Tax (5-6)	87.93	-26.37	19.96	-13.72	0.69
8	Tax Expense	17.50	0.00	0.00	17.50	105.04
9	Net profit (+)/Loss (-) for the period (7-8)	105.43	-26.37	19.96	3.78	-104.35
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	-463.48
12	Earnings Per Share (EPS) - Face Value of Share Rs. 10/ each (Not Annualised)					
	- Basic and diluted	1.05	-0.26	0.20	0.04	-1.04

Notes:

- 1) The above results were Audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 22.05.2016.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 31.03.2016.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah
Managing Director

Date : 22.05.2016
Place : Ahmedabad



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230MH1990PLC058071

STATEMENT OF ASSETS AND LIABILITIES	31.03.2016 Audited	31.03.2015 (Audited)
1. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	-458.35	-463.48
(2) Share Application money pending allotment		
(2) Non - Current Liabilities		
(a) Long Term borrowings	748.93	748.93
(b) Long Term provisions		
(3) Current Liabilities		
(a) Short Term borrowings	2.31	67.32
(b) Trade payables	253.79	279.16
© Other current liabilities	187.02	98.01
(d) Short Term provisions	65.53	92.84
TOTAL	1791.80	1815.35
II. ASSETS		
(1) Non -current assets		
(a) Fixed Assets		
(i) Tangible assets	833.60	861.06
(ii) Capital Work in Progress		
(b) Non Current investments	0.88	0.86
© Deferred tax assets (net)	139.52	122.03
(d) Long Term Loans and Advances	137.69	132.40
(2) Current Assets		
(a) Current investments		
(b) Inventories	341.95	250.03
© Trade Receivables	277.36	376.51
(d) Cash & cash equivalents	-10.76	20.00
(e) Short Term Loans and advances	71.56	52.46
(f) Other Current assets		
	1791.80	1815.35

For Norris Medicines Limited

Vimal D Shah
Managing Director

Date : 22.05.2016
Place : Ahmedabad

**Auditor's Report on Quarterly Financial Results and Year to Date
Results of Norris Medicines Limited Pursuant to the Regulation 33
of the SEBI (LODR) Regulations, 2015**


To,

Board of Directors of
Norris Medicines Limited.

1. We have Audited the Statement of Financial Results of **Norris Medicines Limited** for the quarter ended 31st March, 2016 and the year to date results for the period 01.04.2015 to 31.03.2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the company's management and have been prepared on the basis of the related financial statements prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.
2. Our responsibility is to express an opinion on these financial results. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting policies and the reasonableness of the accounting estimates by the management. We believe that our audit provides reasonable basis for our opinion.

3. In our opinion and to the best of our information and according to the explanations given to us the financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and




(ii) give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit/loss and other financial information of the Company for the year ended 31st March, 2016.

4. The Statement includes the results for the quarter ended 31st March, 2016 being the Balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Place : BHARUCH

Date : 22nd May, 2016

232, Rangoli Complex,
Station Road,
Bharuch - 392 001
Gujarat.



For, **MINU MODI & CO.**
Chartered Accountants

A handwritten signature in blue ink, appearing to read "Minu Modi", written over a horizontal line.

CA MINU MODI
Proprietor
M. No. 100289
(Firm Reg. No. 119948W)



NORRIS
MEDICINES LIMITED







Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230MH1990PLC058071

FORM – A

(Audit Report with unmodified opinion)

Pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulations, 2015

1.	Name of the Company	Norris Medicines Limited
2.	Annual financial statement for the year ended	31 st March, 2016
3.	Type of Audit observation	Un-qualified
4.	Frequency of observation	Not Applicable
5.	To be signed by:	
	Mr. Vimal Dhirendra Shah Managing Director	
	Mr. Iqbal Ismail Patel Chief Financial Officer	
	CA Minu Modi Proprietor M. No. 100289 For M/s Minu Modi & Co. Chartered Accountants F.R. No. 119948W	 
	Mr. Sanjiv Kumar Shah Chairman (Audit Committee)	